Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

FOPO nets $108.2mm for Keryx Biopharmaceuticals

Executive Summary

Renal drug developer Keryx Biopharmaceuticals Inc. netted $108.2mm through the follow-on public offering of 7.9mm common shares (including the overallotment) at $14.50. The company will use the money for pre-launch/launch inventory build-up and pre-commercial/commercial activities for Zerenex. The drug candidate is in Phase III for hyperphosphatemia in end-stage renal disease patients on dialysis and in Phase II for phosphorus and iron deficiency in anemic patients with Stages 3-5 chronic kidney disease.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies